IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats

Core Insights - IQVIA Holdings Inc. is recognized as one of the top 10 life sciences stocks to buy according to hedge funds, indicating strong market interest and potential [1] - Analysts have adjusted their price targets for IQVIA following the company's fourth-quarter results, reflecting changes in market conditions and company performance [2][3] Analyst Ratings and Price Targets - Jailendra Singh from Truist Financial has reiterated a Buy rating for IQVIA, lowering the price target from $290 to $274, which still suggests an upside potential of over 65% [1][2] - Charles Rhyee from TD Cowen has maintained a Hold rating, reducing the price target from $245 to $174, acknowledging potential long-term risks associated with AI but noting current uncertainties [3] Company Overview - IQVIA Holdings Inc. provides a range of services including clinical research, advanced analytics, commercial insights, and market intelligence to the healthcare and life sciences sectors globally [4] - The company specializes in end-to-end clinical trials, offering services such as protocol design, site selection, recruitment, and data analysis, along with cloud-based commercial solutions [4]